Fmc Corporation

Cancer Research Technology Limited

Cephalon, Inc.

Benjamin J Dugan

Bruce D Dorsey

Eugen F Mesaros

Gregory R Ott

George Theodoridis

Craig A Zificsak

Henry Joseph Breslin

Diane E Gingrich

Karen L Milkiewicz

Matthew A Curry

Robert L Hudkins

Allison L Zulli

Emma L Morris

Christelle N Soudy

Zeinab M Elshenawy

Tao Guo

Rabindranath Tripathy

Lester L Maravetz

Ming Tao

James L Diebold

Keith S Learn

Edward J Barron

Stephen F Donovan

Theodore L Underiner

Scott D Crawford

Gregory J Wells

John A Dixson

Joseph Lisko

Jay P Theroff

Gulzar Ahmed

Tho V Thieu

Walter H Yeager

Olga Malsam

Hans-Georg Schwarz

Roland Andree

Christian Arnold

Koc-Kan Ho

Jianming Yu

Eva-Maria Franken

David M Roush

Emma Louise Carswell

Linda Weinberg

Katherine M Fowler

Jason C Wagner

Nathaniel J T Monck

Manorama M Patel

Gregoire A Pave

Ikeoluwa Olowoye

Jonathan R A Roffey

Rong-qiang Liu

Jonathan R Roffey

Jason Burke

Daming Feng

John Francis Chiarello

Mark David Charles

Steven W Szczepanski

Chukuemeka Tennyson Ekwuru

Neil Tremayne

Gurwinder Sidhu

Anne Cochi

Ming You

Fred Elustondo

Frederic Georges Marie Leroux

Nathaniel Jt Monck

Nathaniel JT Monck

Joseph G Lisko

Jonathan Parrish

Karen Milkiewicz

Adolph Bohnstedt

Bruce Dorsey

Jonathan RA Roffey

Emma L Carswell

Henry J Breslin

Rong-Qiang Liu

The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R, R, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

Preparation and uses of pyrimidinone derivatives

The present application provides a compound of formula (I) and/or a salt thereof, wherein R, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Azaquinazoline inhibitors of atypical protein kinase C

The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C ('aPKC') inhibitory activity, and may be used to treat proliferative disorders.

Azaquinazoline inhibitors of Atypical protein Kinase C

The present application provides a compound of formula (I) or a salt thereof, wherein R, R, R, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R, R, R, R, R, and Rare as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors

This application relates to compounds of the general Formula I and salts thereof, wherein X, R, R, R, R, R, and Rare as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

Certain substituted benzylamino heterocyclic and heteroaryl derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula (I): wherein R, R1, R2, R3, and R4 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula (I), and optionally, an effective amount of at least one of an additional compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present. 

Insecticidal substituted benzylamino heterocyclic and heteroaryl derivatives

Certain substituted amino heterocyclic and heteroaryl derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula (I): wherein R, R, R, R, R, A, B and Q are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of an additional compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present. 

Insecticidal substituted amino heterocyclic and heteroaryl derivatives

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders. 

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors

Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, R, R, R, R, b, c, R, R, R, R, R, d, e, U, V, X, WRand Rare fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present. 

Insecticidal N-(heteroarylalkyl)alkanediamine derivatives

Cycloimido-substituted benzofused heterocyclic herbicides

Novel herbicidal compounds, compositions containing them, and methods for their use in controlling weeds are disclosed. The novel herbicidal compounds are represented by formula I: ##STR1## where J is a 1-substituted-6-trifluoromethyl-2,4-pyrimidinedione-3-yl, a 1-substituted-6-trifluoromethyl-1,3,5-triazine-2,4-dion-1-yl, a 3,4,5,6-tetrahydrophthalimid-1-yl, a 4-difluoromethyl-4,5-dihydro-3-methyl-1,2,4-triazol-5(1H)-on-1-yl, a 5,6,7,8-tetrahydro-1H,3H-[1,3,4]thiadiazolo[3,5-a]pyridazineimin-1-yl, or a 1,6,8-triazabicyclo[4.3.0]-nonane-7,9-dion-8-yl ring attached at the 7 position of a benzofuran, benzoxazole, indole, 2,3-dihydrobenzimidazole or benzimidazole, and X is selected from hydrogen, halogen, cyano, nitro, and amino. Preferred R groups are optionally substituted alkyl groups.

Growing community of inventors

Glen Mills, PA, United States of America

Benjamin J Dugan